Eli Lilly and Co.

Indianapolis, Indiana
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk


Eli Lilly scored a 100 out of 100 on the 2023-2024 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with the HRC’s controversial demands, Eli Lilly increases the risk of dividing employees, alienating customers and harming shareholders. The company provides a benefits package for employees which covers transgender medical procedures for covered employees and dependents, including children. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Eli Lilly forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. Eli Lilly offers a Conscious Inclusion program for its employees. The company has also spoken out against state efforts to reform its own election processes and supports the Equality Act. Eli Lilly’s CEO, David A. Ricks, signed the CEO Action for Diversity & Inclusion pledge, which includes a commitment to promote DEI through bias education training in the workplace. The company pledged $25 million to BLM and related causes and denounced religious freedom legislation. Eli Lilly has also funded Planned Parenthood. The company is a copper sponsor of Out & Equal and a corporate partner of the National LGBT Chamber of Commerce. For these reasons, Eli Lilly receives a High Risk rating.

View Full Report

Board Bias

Expand Summary

CEO of Eli Lilly and Co.

David A. Ricks

David A. Ricks


Headquartered in Indianapolis, Indiana, Eli Lilly and Co. is a member of the Fortune 250 operating in the Pharmaceuticals Biotechnology and Life Sciences industry. David A. Ricks and David A. Ricks serve as CEO/President and Chairman, respectively, leading the company’s C-suite executive team and the board of directors. Amongst these teams, the collective leadership is responsible for $314,600 to Republican causes and $109,987 to Democratic causes. Under their tenure, Eli Lilly and Co. currently holds a 'High Risk' risk rating.

View Full Board Bias Report

Political Contributions of Leadership:





Shareholder Proposals

Expand Summary

ESG Category
Summary of ResolutionMgmt RecTotal Vote % in Favor
5/1/23GovernanceJohn CheveddenEliminate Supermajority Voting RequirementsAgainst40.70%
5/1/23GovernanceSEIU Master TrustReport Disclosing Lobbying ActivityAgainst31.40%
5/1/23SocialAs You SowReport on the Effectiveness of the Company's Diversity, Equity, and Inclusion EffortsAgainst27.10%
5/1/23SocialAs You Sow, on behalf of Leslie Oelsner Bene IRA of S Berman (S), Sarah B Sonnenfeld Rev Tr (S), Curtis Overway and Marcelina Cravat-OverwayGreater Disclosure of Material Corporate DiversityAgainst27.10%
5/1/23GovernanceCommonSpirit HealthReport on Lobbying Values CongruencyAgainst22.50%
5/1/23SocialTrinity HealthReport on Impact of Patent Process on Product AccessAgainst10.40%
5/1/23GovernanceChange FinanceRequire Indirect Political Spending ReportingAgainst4.10%
5/1/23SocialNational Center for Public PolicyReport on Risks of Supporting AbortionAgainst1.90%
5/2/22SocialSEIU Master TrustReport on Lobbying Payments and PolicyAgainst37.03%
5/2/22GovernanceLegal & General Invest. Mgmt. America, Inc.Independent Board ChairAgainst34.54%
5/2/22SocialCommonSpirit HealthDisclose Lobbying Activities & Alignment with Public Policy PositionsAgainst34.00%
5/2/22GovernanceTrinity HealthReport Oversight of Risks Related to Anticompetitive Pricing StrategiesAgainst22.78%
Generate Reports